Stock Taper
EARNINGS CALL ARCHIVE 4 CALLS ON FILE
TGTX — TG Therapeutics, Inc.
NASDAQ
FULL STOCK PAGE →

Q4 2025 Earnings Call Summary

FEB 26, 2026
REVENUE
$192.6M +19.1%
NET MARGIN
12.0% -229.8 PTS
EPS
$0.16 -94.1%
FREE CASH FLOW
$19.6M +184.3%

No summary has been written for this call yet.